Precision Oncology aims to use cancer treatments that are targeted to individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics. Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology is paving the way for this individualized patient therapy based on molecular profiles. In this context, physicians must be aware of the clinical evidence behind the NGS tests available, in order to use them in the right moment.
This review will focus on the use of NSG testing for mutations in the epidermal growth factor receptor (EGFR) gene which is the most common targetable genomic drivers in non-small cell lung cancer (NSCLC).Sponsored by the International Association for the Study of Lung Cancer (IASLC). This activity is supportd by an independent educational grant from Johnson & Johnson Innovative Medicine (Janssen).
This CME activities are designed for multidisciplinary teams of medical oncologists, pathologists, histologists, clinical radiation oncologists, pulmonologists, translational scientists, nurses, nurse practitioners, scientists, specialty pharmacists and physician assistants globally.
This activity is supported by an independent educational grant from Johnson & Johnson Innovative Medicine (Janssen).
"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). All other presenters, planners, editors, or staff report no relationshops to disclose:"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."